WANBURYNSEWanbury Limited· PharmaceuticalsHighNeutral
Announced Fri, 29 May · 20:50 IST

Wanbury Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Pat Growth 25pctExceptional ItemResults View source PDF

WANBURY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-16.8%1-day move
₹311.00
prior close
₹286.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.1-6.6-4.2-7.0-16.8-16.7-17.0-14.8-17.9-16.7-12.8-7.3
Up moveDown movePending
AI summary

Wanbury Limited reported audited financial results for Q4 and the full year ended March 31, 2026. Revenue from operations grew 8.5% to ₹65,027 lakhs from ₹59,951 lakhs in the prior year. Profit after tax surged 116.6% to ₹6,613 lakhs from ₹3,053 lakhs, driven by improved margins and lower finance costs. EBITDA margin expanded from approximately 8.8% to 12.0%. The auditors issued an unmodified (clean) opinion with no qualifications. The company recorded an exceptional charge of ₹360.39 lakhs due to new labour code implementation (increase in gratuity and leave liabilities). A deferred tax write-off of ₹551.67 lakhs was also recognized following the company's switch to the new concessional tax regime effective FY 2026-27.

Likely market impact

The stock is likely to see a positive reaction given the strong doubling of PAT and margin expansion. The clean auditor opinion removes key risks. However, the deferred tax write-off and exceptional item are one-time items that inflate current-year profitability.